{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Flora Growth Corp.
Is Flora Growth Corp. overvalued or undervalued?
As of August 9, 2022, Flora Growth Corp. is rated as "risky" due to overvaluation indicated by a Price to Book Value of 3.04, a negative ROCE of -218.48%, and a year-to-date return of -35.85%, despite a recent positive stock return of 10.27%.
Flora Growth Corp. Hits New 52-Week High of $25.70, Surging 2108.7%
Flora Growth Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 25.70 on September 15, 2025, reflecting a significant stock performance increase over the past year. Despite this, the company operates at a loss with negative return on equity and no dividend yield.
Is Flora Growth Corp. overvalued or undervalued?
As of October 1, 2023, Flora Growth Corp. is considered attractive due to its undervalued status with a P/E ratio of 12.5, a P/B ratio of 1.2, and a D/E ratio of 0.4, indicating a strong financial position compared to peers like Aurora Cannabis and Canopy Growth Corp. which have higher P/E ratios.
Is Flora Growth Corp. technically bullish or bearish?
As of November 1, 2023, there is insufficient technical data for Flora Growth Corp. to determine if it is bullish or bearish.
What does Flora Growth Corp. do?
Flora Growth Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $12 million and a net loss of $1 million as of March 2025. It has a market cap of $16.25 million and key metrics indicating financial challenges, including a negative return on equity.
How big is Flora Growth Corp.?
As of Jun 18, Flora Growth Corp. has a market capitalization of 16.25 million and reported net sales of 53.27 million with a net profit of -13.30 million over the latest four quarters. Shareholder's funds were 4.51 million, and total assets were valued at 26.23 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
